WHO flags limited mpox testing in epicenter DR Congo

WHO flags limited mpox testing in epicenter DR Congo

/ 09:28 AM September 15, 2024

WHO flags limited mpox testing in epicenter DR Congo

A nurse stands next to a newly created mpox isolation ward at a civil hospital in Ahmedabad on September 10, 2024. Agence France-Presse

GENEVA — Limited capacity is keeping Mpox testing coverage low in the DR Congo — the epicenter of the international emergency — the World Health Organization said Saturday in its latest situation report.

“Testing coverage in the Democratic Republic of the Congo remains low, due to limited testing capacity,” the UN health agency said in its update.

Article continues after this advertisement

It said the mpox case fatality ratio in the DRC in 2024 was 0.5 percent among confirmed cases — or 25 deaths from 5,160 cases — and 3.3 percent among suspected cases, both tested and untested — or 717 deaths among 21,835 cases.

FEATURED STORIES

READ: Fear grips east DR Congo as displaced await mpox vaccine

“Due to limited access to laboratory testing in remote areas, only about 40 percent of all suspected cases have been tested in 2024 (up from nine percent in 2023), and among these, around 55 percent tested positive,” the WHO said.

Article continues after this advertisement

It said the three countries reporting the most suspected cases in the year up to September 8 were the DRC, followed by Burundi (1,489 suspected cases, no deaths), and Nigeria (935 suspected cases, no deaths).

Article continues after this advertisement

There are two clades of mpox, each with a and b subclades.

Article continues after this advertisement

READ: First mpox vaccines due in DR Congo on Thursday

The WHO said the clades and their subclades were circulating in different geographic areas and were affecting different populations — and therefore needed “tailored and locally-adapted outbreak responses”.

Article continues after this advertisement

The WHO declared an international emergency over mpox on August 14, concerned by the surge in cases of the new Clade 1b strain in the DRC that spread to nearby countries.

In the DRC, Clade 1b has been detected chiefly in the eastern South Kivu and North Kivu provinces, with additional cases in the Kinshasa capital province.

Current sequencing capacity in the DRC “is limited, and clade distribution might be broader than what is currently known” the WHO said.

Clade 1b has also been detected in the DRC’s eastern neighbours Burundi, Rwanda and Uganda, plus Kenya. Additionally, a single case has been detected in Sweden and another in Thailand.

Looking at global vaccine availability, the WHO said more than 3.6 million doses had been pledged for the global response, including more than 620,000 doses of the MVA-BN vaccine by European countries, the United States and manufacturer Bavarian Nordic.

Meanwhile Japan has pledged three million doses of the LC16 vaccine.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

To date, 265,000 MVA-BN doses have been delivered to Kinshasa, while 10,000 have gone to Nigeria.

TAGS: DR Congo, mpox

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.